Possible risk of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Diabetologia

• Publication date

  1997-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s001250050855PMID 9447960
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evidence-based medicine.

  1997cited by this paper
• Managing diabetes after myocardial infarction

  1997cited by this paper
• Insulin infusion in diabetic patients with acute myocardial infarction. Effective components of care and patients who might benefit must be determined.

  1997cited by this paper
• Case-control study of sudden infant death syndrome in Scotland, 1992-5

  1997cited by this paper
• Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited.

  1997cited by this paper
• Insulin infusion in diabetic patients with acute myocardial infarction

  1996cited by this paper
• Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction.

  1996cited by this paper
• The Feasibility of Intensive Insulin Management in Non-Insulin-dependent Diabetes Mellitus: Implications of the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM

  1996influential reference
• Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing?

  1996cited by this paper
• Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year.

  1995cited by this paper

• Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?

  2017cites this paper
• The 'Old' Anti-Diabetic Agents: A Systematic Inventory.

  2016cites this paper
• Cerebrovascular Safety of Sulfonylureas: The Role of KATP Channels in Neuroprotection and the Risk of Stroke in Patients With Type 2 Diabetes

  2016influential citation
• The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus

  2013cites this paper
• Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: more support for cardiovascular outcome assessments.

  2011cites this paper
• Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.

  2011cites this paper
• Safe Oral Antidiabetic Agents in Cardiac Patients: An Update

  2009cites this paper
• Initiating insulin in type 2 diabetes mellitus: the earlier the better.

  2004cites this paper
• Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66.

  2004cites this paper
• Sulfonylureas in the prevention of vascular complications: from UKPDS to the ADVANCE study

  2003cites this paper
• The atherogenic lipid profile is associated with type 2 diabetes and some of its treatment modalities.

  2003cites this paper
• Diabetes mellitus and pharmacological therapy.

  2003cites this paper
• Metabolic effects of mealtime insulin lispro in comparison to glibenclamide in early type 2 diabetes.

  2003cites this paper
• Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications.

  2003cites this paper
• Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?

  2003cites this paper
• Comparison of metformin versus sulphonylurea in combination with daily NPH insulin in patients with type 2 diabetes inadequately controlled on hypoglycaemic agents; median follow‐up“29 months

  2002cites this paper
• Cardiovascular Safety of Oral Antidiabetic Agents: The Insulin Secretagogues

  2002cites this paper
• DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction): theory and practice

  2002cites this paper
• [Should the occurrence of a first coronary event change the management of diabetes?].

  2000cites this paper
• Insulin treatment with preprandial injections of regular insulin in middle-aged type 2 diabetic patients. A two years observational study.

  2000cites this paper
• Current therapeutic options in Type 2 diabetes

  1999cites this paper
• Diabetes and myocardial infarction.

  1999cites this paper
• Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus

  1999cites this paper
• Impact of glucose control in type 2 diabetes: session summary.

  1999cites this paper
• [Type 2 diabetes mellitus and coronary heart disease].

  1999cites this paper
• Herz und metabolisches Syndrom

  1999cites this paper
• Rationale for the use of insulin therapy alone as the pharmacological treatment of type 2 diabetes.

  1999cites this paper
• Effects of oral antihyperglycemic agents in modifying macrovascular risk factors in type 2 diabetes.

  1999cites this paper
• Prognosis and treatment of cardiovascular disease in Diabetes mellitus

  1999cites this paper
• The DIGAMI debate continues

  1999cites this paper
• Diabetes and myocardial infarction: Do we have time to wait?

  1999cites this paper
• Possible risk of sulphonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease

  1998influential citation
• International Diabetes Federation Meeting, 1997, and Other Recent Meetings: Atherosclerosis and related topics

  1998cites this paper
• Diabetes mellitus and myocardial infarction: a time to act or a time to wait?

  1998cites this paper
• Group specific component protein genotype is associated with NIDDM in Japan

  1998cites this paper